Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859648 · ClinicalTrials.gov registry record · NA
BONEBRIDGE Bone Conduction Implant in Adults
A NA study, sponsored by Med-El Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03859648: Clinical Trial NA study, sponsored by Med-El Corporation.
NCT03859648 is a NA study that was terminated before completion, run by Med-El Corporation. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03859648, a NA study, was terminated before completion, sponsored by Med-El Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Approximately thirty subjects with mixed or conductive hearing loss, meeting FDA-cleared candidacy criteria for the BONEBRIDGE, will be implanted and followed for three (3) months post-activation to assess safety and effectiveness of the BONEBRIDGE implant.
Primary Outcome
Adverse events will be collected and reported throughout the duration of the study.
Interventions
- DEVICE BONEBRIDGE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
Why NCT03859648 stopped before completion
NCT03859648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which BONEBRIDGE is the first listed.
NCT03859648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03859648 about?
NCT03859648 is a clinical study titled "BONEBRIDGE Bone Conduction Implant in Adults". Approximately thirty subjects with mixed or conductive hearing loss, meeting FDA-cleared candidacy criteria for the BONEBRIDGE, will be implanted and followed for three (3) months post-activation to assess safety and effectiveness of the BONEBRIDGE implant.
What is the current status of trial NCT03859648?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2019-08-26. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT03859648?
The interventions under investigation include: BONEBRIDGE (DEVICE).
Who is sponsoring clinical trial NCT03859648?
This trial is sponsored by Med-El Corporation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03859648's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI